Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01277107 · ClinicalTrials.gov registry record · Phase 2

A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia

A Phase 2 study of Insomnia, sponsored by Intec Pharma.

Completed
Registry status
Phase 2
Development phase
83
Enrollment target
6
Study locations

NCT01277107: Completed Phase 2 study of Insomnia, sponsored by Intec Pharma.

NCT01277107 is a Phase 2 study of Insomnia that has completed, run by Intec Pharma. The registered enrollment target is 83 participants, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (51% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01277107, a Phase 2 study of Insomnia, has completed, sponsored by Intec Pharma.

COMPLETED
Registry status
Phase 2
Development phase
83 participants
Enrollment target
6
Study locations

Study Summary

This is a multi center, double blind placebo controlled, two-way crossover study in patients with Insomnia suffering from difficulty in falling asleep and staying asleep. This study intends to assess the efficacy of Zaleplon AP in improving sleep parameters, comparing to placebo.

Primary Outcome

The change from baseline on the mean of drug nights 1 and 2 relative to placebo.

Conditions Studied

Interventions

  • DRUG Placebo capsule
  • DRUG Zaleplon AP formulation

Study Locations (6)

Florida

  • Miami Research Associates - Miami
  • Broward Research Group - Pembroke Pines
  • CRG of St. Petersburg - St. Petersburg

California

  • Pacific Sleep Medicine - San Diego

Kansas

  • Vince and Associates Clinical Research - Overland Park

Other

  • Rambam sleep center - Haifa

Trial Details

FieldValue
Enrollment Target 83 participants
Start Date 2011-01
Est. Completion 2011-09
Phase Phase 2
Intec Pharma

1 total trials

What the finished NCT01277107 record still lists

NCT01277107 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 170-participant average among 151 other Insomnia trials with a reported enrollment target (51% lower).

The record links to 1 condition, with Insomnia appearing as the primary indexed condition, and to 2 interventions - of which Placebo capsule is the first listed.

NCT01277107 lists 6 locations in 4 states (Florida, California, Kansas).

Frequently Asked Questions

What is clinical trial NCT01277107 about?

NCT01277107 is a clinical study titled "A Polysomnographic Study to Compare the Efficacy of Gastric Retentive Zaleplon Accordion Pill to Placebo in Subjects With Insomnia". This is a multi center, double blind placebo controlled, two-way crossover study in patients with Insomnia suffering from difficulty in falling asleep and staying asleep. This study intends to assess the efficacy of Zaleplon AP in improving sleep parameters, comparing to placebo.

What is the current status of trial NCT01277107?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2011-01. Estimated completion is 2011-09.

What conditions does trial NCT01277107 study?

This clinical trial studies the following conditions: Insomnia.

What interventions are being tested in trial NCT01277107?

The interventions under investigation include: Placebo capsule (DRUG), Zaleplon AP formulation (DRUG).

Who is sponsoring clinical trial NCT01277107?

This trial is sponsored by Intec Pharma, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01277107 being conducted?

This trial has 6 study locations across California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insomnia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01277107's enrollment target sits among peer trials

83 72nd of 151 higher than 79 of 151 other Insomnia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Insomnia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02974647 · 83 participants · Phase 2

    Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

  • NCT03919292 · 83 participants · Phase 1

    Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

  • NCT04626674 · 83 participants · Phase 1

    A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

  • NCT05277168 · 83 participants · Phase 1

    A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01277107, the US trial registry maintained by the National Library of Medicine. NCT01277107 (small enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.